In short. Each component carries its own approval on its own indication, and the combination is a clinical decision rather than a regulated entity. What that means.
Key points
- Approval and evidence are separate questions throughout this cluster, and nowhere more than here.
- A combination can be reasonable clinical practice and carry no approval whatever.
- What it cannot do is borrow an approval from one of its components and present that as though it covered the plan.
Regulation in this field is component by component, and there is no level at which a combined plan is approved. Understanding why is the fastest way to see what an approval claim does and does not cover.
Three kinds of thing, three kinds of approval
An operation is a procedure, not a product, so it is governed through the licensing of the surgeon, the accreditation of the institution and standards of care rather than through a product approval. An injectable substance is a product, and it is approved for a defined use in a defined market. A device is approved for a defined indication, and that approval belongs to the device rather than to the family it sits in. Each of those is narrow and specific, and each is granted separately.
Why there is no combination approval
Nothing in that structure has a slot for a plan. A regulator approves a product for an indication; it does not approve a combination of a procedure and a product, because a combination is not something that can be manufactured, labelled or recalled. It is a decision made about one person at one time. The consequence is that the combination has no regulatory status at all, which is not a finding about its safety and not a finding about its effectiveness either.
No approval is not the same as no evidence
Approval and evidence are separate questions throughout this cluster, and nowhere more than here. A combination can be reasonable clinical practice and carry no approval whatever. What it cannot do is borrow an approval from one of its components and present that as though it covered the plan.
Where responsibility sits
Because no regulator reviews the combination, the reasoning and the responsibility sit with the clinician who proposed it. That has two practical consequences for a reader. The first is that the explanation behind a hybrid plan is not a courtesy; it is the only accountability the plan has, and it is reasonable to expect it in words. The second is that a page implying the combination is approved, cleared or established as a standard of care has moved from a fact about a product to a claim about a plan without saying so.
Approval claims that do not hold
- A component approval presented as covering the combined plan.
- A combination described as approved when only the product inside it is.
- A clearance in one market described as though it applied to the plan everywhere.
Reported separately, approval and evidence are both useful. Merged into one sentence, they are neither.
Frequently asked questions
Is a combined treatment plan approved by a regulator?
No. Regulators approve products, devices and indications, and a combination of an operation with a non-surgical treatment is none of those. The combination is a clinical decision made for one person by a clinician, and its justification is the reasoning behind it rather than an approval.
What is each component approved for?
The operation is governed through the licensing of the surgeon and the institution rather than approved as a product. The injectable is approved as a product for a defined use. The device is approved for a defined indication in a defined jurisdiction. Each of those is specific, and none of them extends to the plan as a whole.
Who is responsible for a combined plan?
The clinician who makes it. Because no regulator approves the combination and no study has established it as a standard, the reasoning and the responsibility sit with the person who proposed it. That is why the explanation behind a hybrid plan is worth asking for, and why it is reasonable to expect one.
Risks & Limitations
- Hybrid means combining modalities in one plan and one treatment episode, which is not the same as sequencing treatments over time.
- Each component is approved on its own indication, and no regulator approves the combination or a better result from it.
- More treatment in one episode adds to the risk rather than distributing it, because the tissue heals from more than one insult at once.
- That a combined plan beats staging, defers an operation or reduces total treatment is not established by the evidence.
- A combined result is harder to attribute, because swelling from one component distorts how the other reads.
When to Seek Care
- Increasing pain, spreading redness or warmth, or a fever after any treatment — have it assessed urgently.
- A wound that opens, or discharge from a wound — contact the service that performed the treatment.
- A change in vision, speech or skin colour after an injectable — seek emergency care immediately.
- A firm lump, a nodule, or skin that becomes dusky or painful after an injectable is assessed by a clinician rather than watched.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — approved products, devices and their labelled indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page and it does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.